Published in Vaccine Weekly, October 27th, 2004
"The U.S. government's decision to further develop and acquire Imvamune recognizes the advanced stage of our clinical research program and the need for a safe vaccine for the American public," said Peter Wulff, CEO, Bavarian Nordic.
"Ultimately, it is essential that the United States stockpiles a single, safe and effective smallpox vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly